Knockdown of HMGB1 inhibits growth and invasion of gastric cancer cells through the NF-κB pathway in vitro and in vivo

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1268-1276

  Zhang, Jing ^a   Kou, Yu Bin ^b   Zhu, Jin Shui ^a   Chen, Wei Xiong ^a   Li, Shuang ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Gastric cancer; Growth; HMGB1; Invasion

Indexed keywords

CYCLINE; GELATINASE B; HIGH MOBILITY GROUP B1 PROTEIN; HMGB1 PROTEIN, HUMAN; MESSENGER RNA; RELA PROTEIN, HUMAN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA;

ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL MOTION; CELL PROLIFERATION; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; MIDDLE AGED; MOUSE; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; STOMACH; STOMACH TUMOR; TUMOR CELL LINE; TUMOR INVASION; WOUND HEALING; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB1 PROTEIN; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROLIFERATING CELL NUCLEAR ANTIGEN; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; STOMACH; STOMACH NEOPLASMS; TRANSCRIPTION FACTOR RELA; TRANSPLANTATION, HETEROLOGOUS; WOUND HEALING;

EID: 84894429699     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2285     Document Type: Article

References (35)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Tajima Y, Yamazaki K, Makino R, et al: Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: clinicopathologic significance and genetic background. Clin Cancer Res 12: 6469-6479, 2006. (Pubitemid 44799720)
3. Asavarut P, Zhao H, Gu J and Ma D: The role of HMGB1 in inflammation-mediated organ injury. Acta Anaesthesiol Taiwan 51: 28-33, 2013.
4. Nogueira-Machado JA and de Oliveira Volpe CM: HMGB-1 as a target for inflammation controlling. Recent Pat Endocr Metab Immune Drug Discov 6: 201-209, 2012.
5. Teiten MH, Gaigneaux A, Chateauvieux S, et al: Identification of differentially expressed proteins in curcumin-treated prostate cancer cell lines. OMICS 16: 289-300, 2012.
6. Chen J, Xi B, Zhao Y, et al: High-mobility group protein B1 (HMGB1) is a novel biomarker for human ovarian cancer. Gynecol Oncol 126: 109-117, 2012.
7. Kostova N, Zlateva S, Ugrinova I and Pasheva E: The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem 337: 251-258, 2010.
8. Sterenczak KA, Joetzke AE, Willenbrock S, et al: High-mobility group B1 (HMGB1) and receptor for advanced glycation end-products (RAGE) expression in canine lymphoma. Anticancer Res 30: 5043-5048, 2010.
9. Choi J, Lee MK, Oh KH, et al: Interaction effect between the receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line. Tumori 97: 196-202, 2011.
10. Yao X, Zhao G, Yang H, et al: Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 136: 677-684, 2010.
11. Liu Y, Xie C, Zhang X, et al: Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer 46: 3007-3015, 2010.
12. Tang CH, Keng YT and Liu JF: HMGB-1 induces cell motility and α5β1 integrin expression in human chondrosarcoma cells. Cancer Lett 322: 98-106, 2012.
13. Mardente S, Mari E, Consorti F, et al: HMGB1 induces the overexpression of miR-222 and miR-221 and increases growth and motility in papillary thyroid cancer cells. Oncol Rep 28: 2285-2289, 2012.
14. Yan W, Chang Y, Liang X, et al: High mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology 55: 1863-1875, 2012.
15. Lee H, Song M, Shin N, et al: Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS One 7: e34318, 2012.
16. Liu L, Yang M, Kang R, et al: HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 25: 23-31, 2011.
17. Yang L, Yu Y, Kang R, et al: Up-regulated autophagy by endogenous high mobility group box-1 promotes chemoresistance in leukemia cells. Leuk Lymphoma 53: 315-322, 2012.
18. Sterenczak KA, Kleinschmidt S, Wefstaedt P, et al: Quantitative PCR and immunohistochemical analyses of HMGB1 and RAGE expression in canine disseminated histiocytic sarcoma (malignant histiocytosis). Anticancer Res 31: 1541-1548, 2011.
19. RQ Peng, XJ Wu, Y Ding, et al: Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer. BMC Cancer 10: 496, 2010.
20. Jiao Y, Wang HC and Fan SJ: Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 28: 1957-1967, 2007. (Pubitemid 350198338)
21. Hanahan D and Weinberg RA: The hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
22. Sun KK, Ji C, Li X, et al: Overexpression of high mobility group protein B1 correlates with the proliferation and metastasis of lung adenocarcinoma cells. Mol Med Rep 7: 1678-1682, 2013.
23. Wang W, Jiang H, Zhu H, et al: Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma. Oncol Lett 5: 884-888, 2013.
24. van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, et al: Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene 32: 363-374, 2013.
25. Wild CA, Brandau S, Lotfi R, et al: HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol 48: 409-416, 2012.
26. Mao XJ, Wang GF, Chen ZJ, et al: Expression of HMGB1 and its clinical significance in T-cell lymphoma. Asian Pac J Cancer Prev 13: 5569-5571, 2012.
27. Dong YD, Cui L, Peng CH, et al: Expression and clinical significance of HMGB1 in human liver cancer: knockdown inhibits tumor growth and metastasis in vitro and in vivo. Oncol Rep 29: 87-94, 2013.
28. Akaike H, Kono K, Sugai H, et al: Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer. Anticancer Res 27: 449-457, 2007.
29. Kang R, Tang D, Schapiro NE, et al: The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene: Jan 14, 2013 (Epub ahead of print). doi: 10.1038/onc.2012.631.
30. Liang X, Chavez AR, Schapiro NE, et al: Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol 86: 599-607, 2009.
31. Zhang J, Zhu JS, Zhou Z, et al: Inhibitory effects of ethyl pyruvate administration on human gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways in vitro and in vivo. Oncol Rep 27: 1511-1519, 2012.
32. Weng H, Deng Y, Xie Y, et al: Expression and significance of HMGB1, TLR4 and NF-κB p65 in human epidermal tumors. BMC Cancer 13: 311, 2013.
33. Czyzewska J, Guzińska-Ustymowicz K, Lebelt A, et al: Evaluation of proliferating markers Ki-67, PCNA in gastric cancers. Rocz Akad Med Bialymst 49: 64-66, 2004.
34. Cawston TE and Wilson AJ: Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 20: 983-1002, 2006. (Pubitemid 44356460)
35. Park SK, Hwang YS, Park KK, et al: Kalopanaxsaponin A inhibits PMA-induced invasion by reducing matrix metalloproteinase-9 via PI3K/Akt- and PKCdelta-mediated signaling in MCF-7 human breast cancer cells. Carcinogenesis 30: 1225-1233, 2009.